US biotech companies are worried that recommendations of a government task force on gene patenting and licensing, if implemented, could restrict the ability to obtain, or undermine the enforceability of, patents and exclusive licences with respect to genetic tests, according to the Biotechnology Industry Organization1,2
...
Please Login to read the full article.
